Physician profile
Julie Polisiakiewicz
NPI 1184918351
$2,614.51
in general payments reported to CMS, 2019-2025
22 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $33.87 · 2023: $867 · 2024: $936 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $850 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $850.00 | 2023 | Powerpicc |
| Glaxosmithkline, LLC. | $472.80 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $251.09 | 2024-2025 | Airsupra, Fasenra, Breztri |
| Genzyme Corporation | $119.60 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.65 | 2024-2025 | Aralast |
| Vapotherm INC | $101.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Genentech USA, INC. | $78.61 | 2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $72.78 | 2024-2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $68.28 | 2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $52.89 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $52.31 | 2023-2024 | |
| Philips North America LLC | $40.71 | 2024 | (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.81 | 2024-2025 | Jascayd, Ofev |
| Grifols USA, LLC | $36.44 | 2025 | Prolastin-C Liquid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $33.87 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $31.63 | 2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $27.80 | 2024 | Yupelri |
| Harmony Biosciences LLC | $20.61 | 2025 | |
| Insmed, INC. | $18.57 | 2025 | Brinsupri, Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2024 | |
| Axsome Therapeutics, INC. | $15.88 | 2024 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Polisiakiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.